Hexarelin Acetate from Super Human Peptides UK is a synthetic hexapeptide belonging to the Growth Hormone-Releasing Peptide (GHRP) class. In laboratory research, Hexarelin is recognized as one of the most potent growth hormone secretagogues available. Researchers utilize this compound to study the maximum limits of pituitary growth hormone pulsatility and to investigate the rapid desensitization (down-regulation) of GH receptors.
Beyond the somatotropic axis, Hexarelin is highly unique due to its binding affinity for CD36 receptors in cardiac tissue, making it a major subject of research in cardiovascular protection and ischemic heart disease models. Produced under GMP-compliant conditions and verified for 99% purity or higher, Hexarelin Acetate is a powerful tool for advanced endocrine and cardiology research.
WarningFor laboratory research use only. Not for human consumption.
Key Features
- —High Potency: Known to elicit a massive release of endogenous growth hormone in animal models.
- —Maximum Purity: 99% purity or higher (verified by HPLC and MS analysis).
- —Cardiovascular Modelling: Unique affinity for cardiac CD36 receptors.
- —Quality Standard: GMP / ISO certified manufacturing.
Research Focus
- —Maximum GH Pulsatility: Studying the peak limits of growth hormone release compared to other GHRPs.
- —Receptor Down-Regulation: Investigating the rapid desensitization of pituitary receptors during continuous administration.
- —Cardioprotection: Research into the prevention of ischemic injury and cardiac remodeling via CD36 activation.
- —Endocrine Feedback: Measuring secondary elevations in cortisol and prolactin levels, which are notably higher with Hexarelin than with Ipamorelin.
- —Body Composition: Preclinical models evaluating rapid lipolysis and lean muscle tissue retention under stress.
Published Research and Study Findings
Hexarelin is frequently cited in literature for its sheer potency. Laboratory studies comparing Hexarelin to GHRP-6 and Ipamorelin consistently show that Hexarelin produces the largest spike in growth hormone. However, research also indicates that continuous use in animal models leads to rapid receptor desensitization, causing the GH-releasing effect to diminish after several weeks—a key area of study for receptor kinetics.
Interestingly, much of the recent research focus has shifted to its cardiovascular properties. Studies by Bisi et al. and others have demonstrated that Hexarelin can protect heart tissue from ischemia-reperfusion injury and improve left ventricular function in aged or damaged animal hearts, operating through pathways entirely independent of growth hormone release.
NoteAll findings are derived from laboratory and non-clinical research settings.
Representative Scientific References
- 1.Bisi, G. et al., "Cardiac effects of hexarelin in experimental and clinical studies," Cardiovascular Research, 1999.
- 2.Ghigo, E. et al., "Growth hormone-releasing peptides," European Journal of Endocrinology, 1997.
- 3.Massoud, A.F. et al., "Hexarelin-induced growth hormone, cortisol and prolactin release: a dose-response study," The Journal of Clinical Endocrinology and Metabolism, 1996.
- 4.Bodart, V. et al., "Identification and characterization of a new growth hormone-releasing peptide receptor in the heart," Circulation Research, 1999.
